AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie AbbVie Share of Venclexta U.S. S&M Collaboration Costs by Year
AbbVie Share of Venclexta U.S. S&M Collaboration Costs [annual] ($M) ($M)
AbbVie AbbVie Share of Venclexta U.S. S&M Collaboration Costs: $28M in FY2025, down 3.4% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 5 Licensing, Acquisitions & Other Arrangements.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AbbVie Share of Venclexta U.S. S&M Collaboration Costs [annual] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28 | -3.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 29 | -29.3% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 41 | +10.8% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 37 | -7.5% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 40 | -13.0% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 46 | +12.2% | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 41 | +51.9% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 27 | – | Form 10-K (filed 2021-02-19) ↗ |
Cite this data
StockData. (2026). AbbVie AbbVie Share of Venclexta U.S. S&M Collaboration Costs ($M), annual FY2018–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/collab-genentech-sga
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.